A new study led by researchers at the Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC –… read more.
Encouraging safety and efficacy data on novel and emerging therapies presented at the 54th Annual Meeting of the American Society of Haematology (ASH) signal an important step forward… read more.
Studies of stem cell biology and transplant approaches presented at the 54th Annual Meeting of the American Society of Haematology (ASH) illustrate how the use of advanced modelling… read more.
by Sung Choi, M.D., University of Michigan Comprehensive Cancer Center (pictured) First study in humans shows promise for preventing graft-versus-host disease following bone marrow transplant.
An experimental drug combination for preventing graft-versus-host disease (GVHD) was not significantly better than the standard regimen on key endpoints, according to a report of a phase 3… read more.
Proof-of-concept animal study selected as one of the best presentations at 54th American Society of Hematology Annual Meeting and Exposition.
by Edel O’Connell reporting on the presentation by Professor Alain Carpentier.
by Bruce Sylvester – Emerging use of FDA Approved Drugs – Maraviroc, an antiretroviral drugin the treatment of HIV, significantly reduces the incidence of graft-versus-host disease (GvHD) among… read more.
by Bruce Sylvester – Emerging uses of FDA Approved Drugs – In some patients severe aplastic anemia who have failed standard therapies, eltrombopag appears to raise blood cell… read more.
by Maria Dalby – Biopsies taken one year after renal transplantation could be used for identifying patients at high risk of graft failure.
by Maria Dalby – Efforts continue to develop new anti-rejection agents that are as effective as the calcineurin inhibitors (CNI) but without the debilitating side effects.
by Maria Dalby – Almost all lung transplant recipients will develop bronchiolotis obliterans (BO) if they live long enough – as transplantation care is improving, BO is becoming… read more.
Advertisment
If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.
You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.
